×
Palvella Therapeutics Net Profit Margin 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Palvella Therapeutics net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Palvella Therapeutics Net Profit Margin 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Palvella Therapeutics net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$151.4B
Bristol Myers Squibb (BMY)
$119.8B
Gilead Sciences (GILD)
$119.1B
Vertex Pharmaceuticals (VRTX)
$113.7B
CSL (CSLLY)
$83.5B
Regeneron Pharmaceuticals (REGN)
$75.5B
GSK (GSK)
$72.7B
Argenex SE (ARGX)
$39.5B
Alnylam Pharmaceuticals (ALNY)
$35.3B
BioNTech SE (BNTX)
$29B
BeiGene (ONC)
$22.2B
Biogen (BIIB)
$21B
Illumina (ILMN)
$20.9B
Moderna (MRNA)
$15.7B
Incyte (INCY)
$14.2B
Insmed (INSM)
$14B
Intra-Cellular Therapies (ITCI)
$13.5B
Genmab (GMAB)
$13.1B
Genmab (GNMSF)
$12.9B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.4B
Vaxcyte (PCVX)
$11.1B
Sarepta Therapeutics (SRPT)
$11B
Exact Sciences (EXAS)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Bio-Rad Laboratories (BIO.B)
$10B
QIAGEN (QGEN)
$9.7B
Repligen (RGEN)
$9.5B
Exelixis (EXEL)
$9.4B
Roivant Sciences (ROIV)
$8.1B